GleamWall
中文EN

TRIB TRINITY BIOTECH PLC IFRS

In Vitro & In Vivo Diagnostic Substances · Nasdaq · SEC CIK 888721 · Fiscal year ends 12/31

Financial factors as of 2020-12-31 (FY2020), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY12.8%
TTM net income YoY77.9%
TTM EPS YoY—
Revenue 3-yr CAGR0.9%
Net income 3-yr CAGR—

Margins

Gross margin47.6%
Operating margin0.1%
Net margin-6.3%
FCF margin20.2%
EBITDA margin0.1%

Returns

ROE-512.3%
ROA-4.9%
ROIC (approx.)0.1%
Asset turnover0.78x

Leverage & solvency

Liabilities / assets101.7%
Debt / equity—
Current ratio3.08x
Interest coverage0.01x

Cash quality & payout

Operating cash flow / net income-3.72x
Accruals ratio-23.1%
Payout ratio—
Capex / revenue3.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2018Q2*2018-06-302017Q2*2017-06-30
Income statement
Revenue$25.00M$25.45M
Cost of revenue$14.19M$14.63M
Gross profit$10.81M$10.82M
R&D expense$1.42M$1.32M
SG&A expense$7.36M$7.56M
Operating income$1.73M$1.83M
Interest expense$1.16M$1.17M
Pretax income$764,000$859,000
Income tax$158,000$176,000
Net income$594,000$902,000
EPS (basic)2.804.10
EPS (diluted)6.706.80
Weighted avg. shares (diluted)26.16M27.10M
Balance sheet
Cash & equivalents$49.43M$63.98M
Receivables$23.14M—
Inventory$34.82M—
Current assets$108.67M—
PP&E, netmay include right-of-use assets (IFRS)$7.77M—
Total assets$194.45M—
Current liabilities$20.80M—
Total liabilities$127.75M—
Shareholders' equity$66.69M—
Cash flow statement
Operating cash flow$1.74M$3.37M
Financing cash flow-$3.88M-$3.19M
Stock-based compensation$329,000$130,000

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.